RxDoctor Payments Data

Alexander Lakner, DPM

Podiatrist · Greenbelt, MDNPI 1578125399

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.8% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Kerecis Limited at 32.6% of the total. Reporting peaked in 2024 at $824 and has fallen 55.6% since, to $366 in 2025.

$1,762in general payments, 2019–2025

Across 28 payments — averaging $62.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kerecis Limited$574
  • Smith+Nephew$245
  • Supreme Orthopedic Systems, LLC$207
  • Accufix Surgical Inc.$132
  • Convatec Inc.$125
  • Paratek Pharmaceuticals, Inc.$119
  • plus $359 from 7 others

What the payments were for

  • Travel & lodging$211%
  • Food & beverage$1,74099%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Kerecis Limited6$574
Smith+Nephew5$245
Supreme Orthopedic Systems, LLC4$207
Accufix Surgical Inc.1$132
Convatec Inc.1$125
Paratek Pharmaceuticals, Inc.1$119
Integra Lifesciences Corporation2$112
Mimedx Group, Inc.1$81
Native Surgical, LLC2$48
Biowound Solutions, Inc.2$42
Amgen1$28
Globus Medical1$27
Progenacare Global, LLC1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,762 in reported general payments places this provider in the 65th percentile of 183 podiatrist providers in Maryland.

See all podiatrist providers in Maryland

Medicare billing

Part B allowed, 2024
$263,930
Medicare patients
287
Services billed
1,728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Terbinafine Hcl26$256

Paid to pharmacies, not to this prescriber.

Other podiatrist in Greenbelt

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →